tirzepatide surpass Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT Inside SURPASS-CVOT With Dr. Stephen

Its preclinical research profile includes accelerated healing of tendons, ligaments, muscles, bones, and GI mucosa

These hormones play a role in fat metabolism, appetite regulation, and blood sugar control in research subjects

Also, keep track of exactly when you take your medications

In the Phase 2 obesity trial published in NEJM in 2023, retatrutide at the 12 mg weekly dose produced a mean placebo-adjusted body weight reduction of 22.1 percentage points (22.1% (24.2% arm) mean absolute reduction on the retatrutide arm) at 48 weeks (Jastreboff et al., NEJM, 2023)

Studies on the increases of CSF t-tau and A42 in MCI patients have examined NPS in general rather than individual specific symptoms